¸´µ©´óѧNature×Ó¿¯·¢ÎÄÌá³öÖ¬ÖÊÌåµÝËÍÐÂ˼·
¸´µ©´óѧ»ù´¡Ò½Ñ§ÔºµÄÑо¿ÈËÔ±·¢±íÁËÌâΪ¡°Enhanced Immunocompatibility of Ligand-targeted Liposomes by Attenuating Natural IgM Absorption¡±£¨½µµÍÌìÈ»IgMÎü¸½¿ÉÔöÇ¿°ÐÏòÖ¬ÖÊÌåÃâÒßÏàÈÝÐÔ£©µÄÎÄÕ£¬½ÒʾÁËÎȶ¨ÐͶàëÄ·Ö×Ó¶ÔÄÔ°ÐÏòÖ¬ÖÊÌåÌåÄÚµÝËÍ·¢»Ó¡°Ë«Èн£¡±µÄµ÷½Ú»úÖÆ£¬²ûÃ÷±íÃæÎü¸½ÌìÈ»IgM¿ÉÄæÏòµ÷¿ØÄÔ°ÐÏòÖ¬ÖÊÌåµÄÃâÒßÏàÈÝÐÔ¡£Õë¶ÔÒ©ÎïÈëÄÔÄÑÌ⣬¸Ã¹¤×÷Ïà¹Ø³É¹ûΪ¿ÉÖÎÁÆÄÔ²¿¼²²¡£¨ÈçÄÔÖ×ÁöºÍÉñ¾ÍËÐÐÐÔ¼²²¡µÈ£©µÄÖ¬ÖÊÌåÒ©ÎïÉè¼ÆÌṩÐÂ˼·¡£
ÕâÒ»Ñо¿³É¹û¹«²¼ÔÚ7ÔÂ30ÈÕNature CommunicationsÔÓÖ¾ÉÏ£¬ÎÄÕµÄͨѶ×÷ÕßΪ¸´µ©´óѧռ²ýÓÑÑо¿Ô±£¬µÚÒ»×÷ÕßΪ¹Ù¾êºÍÉòÇì¡£
Ö¬ÖÊÌåÒ©Îï±íÃæÐÞÊΰÐÏò¶àëÄ·Ö×Ó£¬¿É¾ÊÜÌå½éµ¼·½Ê½½«Ò©ÎïµÝËÍÖÁ°Ð²¿Î»£¬ÒÔÆÚÌá¸ßҩЧ²¢½µµÍ¶¾¸±×÷Óᣵ«¸ÃÀà°ÐÏòÖ¬ÖÊÌå½øÈëÌåÄÚºó£¬ÑªÒº»ò°ûÄÚÈÜøÌåµÈº¬Óеĵ°°×ø¿É¿ìËÙ½µ½âÖ¬ÖÊÌå±íÃæÐÞÊζàëÄ·Ö×Ó£¬ÑÏÖØÍþвÆäÎȶ¨ÐÔ¡£
¸´µ©´óѧ»ù´¡Ò½Ñ§ÔºÕ¼²ýÓÑ¿ÎÌâ×éÓëҩѧԺ½ΰԾ¿ÎÌâ×éǰÆÚÀûÓÃÄæÐò-Òì¹¹£¨Retro-Inverso Isomerization£©¼¼ÊõÉè¼Æ»ñµÃÁËÎȶ¨ÐͶàëÄ·Ö×Ó£¬ÆäøÎȶ¨ÐÔ´ó´óÌá¸ß£¬ÇÒ±£ÁôÊÜÌå½áºÏ»îÐÔ£¬½éµ¼Ö¬ÖÊÌåÒ©ÎïµÄ°ÐÏòµÝËÍ£¨Mol pharm 2014£¬ 11 (10)£¬3261-8¡¢Angew Chem Int Ed 2015£¬54£º3023-3027ºÍJ Control Release 2015£¬218£º13-21£©¡£
¸ÃÑо¿½á¹û±íÃ÷£¬ºÉÕýµçµÄÎȶ¨Ðͳ¤ëÄ·Ö×Ó¶ÔÖ¬ÖÊÌåµÄÌåÄÚÐÐΪ·¢»Ó¡°Ë«Èн£¡±×÷Ó㬼´¸ÃÀà·Ö×Ó¿ÉÌá¸ßÎȶ¨ÐÔÒÔ±£ÁôÉúÎï»îÐÔ£»µ«ÔÚѪҺѻ·¹ý³ÌÖУ¬°ÐÏòÖ¬ÖÊÌåÒ×´óÁ¿Îü¸½ÌìÈ»IgM£¬¼Ó¾çÁË»úÌåÃâÒßϵͳ¶ÔÖ¬ÖÊÌåµÄʶ±ð¶øÐî»ýÓÚ¸ÎÆ¢£¬Ê¹Ö¬ÖÊÌåѪҺѻ·Ê±¼äÖè¼õ£¬¼ÓËÙÌåÄÚÇå³ý¡£
Ϊ´Ë¿ÎÌâ×éÀûÓüÆËã»ú¸¨ÖúÉè¼ÆºÍµ÷½Ú¸ÃÎȶ¨ÐͶàëÄ·Ö×ӽṹ£¬Èç¼õÉÙÕýµçºÉÊýÄ¿²¢Ëõ¶Ì¶àëij¤¶È£¬ÓÐЧ½µµÍÁËÖ¬ÖÊÌå±íÃæÌìÈ»IgMµÄÎü¸½Á¿£¬³É¹¦Ìá¸ßÆäÃâÒßÏàÈÝÐÔ£¬½µµÍ°ÐÏòÖ¬ÖÊÌåµÄÃâÒßÔÐÔ²¢ÑÓ³¤ÑªÑ»·Ê±¼ä¡£¸ÃÑо¿½ÒʾÁËÎȶ¨ÐͶàëÄ·Ö×ӽ鵼µÄ°ÐÏòÖ¬ÖÊÌåÌåÄÚµÝË͵÷½Ú»úÖÆ£¬Ò²Îª°ÐÏòÖ¬ÖÊÌåµÄÈ«ÃæÓÅ»¯Éè¼ÆÌṩÐÂ˼·¡£
ÔÎıêÌ⣺
Enhanced Immunocompatibility of Ligand-targeted Liposomes by Attenuating Natural IgM Absorption